1. Meaning 

Commercial Embryo Governance refers to the legal, regulatory, ethical, and institutional framework governing the creation, storage, use, transfer, research, and commercial exploitation of human embryos in assisted reproductive technologies (ART), including in-vitro fertilisation (IVF).

The concept addresses how the law should regulate fertility clinics, embryo banks, biotechnology companies, reproductive researchers, intended parents, and gamete donors while protecting human dignity, reproductive autonomy, informed consent, and the welfare of children born through assisted reproduction.

An embryo created through IVF can have significant medical, personal, scientific, and ethical importance. It may be intended for implantation, cryopreservation, donation where lawful, or authorised research. Commercial interests arise from the services surrounding embryos, such as IVF treatment, laboratory work, storage, and biotechnology research.

The central legal question is:

How can the law permit legitimate reproductive medicine without allowing human embryos to become objects of unrestricted sale, trafficking, exploitation, or profit-driven manipulation?

An important distinction is that the term Commercial Embryo Governance is an analytical legal concept, not the name of one universally recognised statute or a single established legal doctrine.

2. Objectives of commercial embryo governance

The principal objectives include:

Preventing embryo trafficking: Prohibiting unlawful sale, purchase, and commercial transfers of human embryos.

Protecting informed consent: Ensuring that the people whose gametes were used understand and authorise the intended use of embryos, subject to applicable law.

Regulating fertility clinics: Requiring appropriate registration, professional qualifications, recordkeeping, and compliance with clinical standards.

Protecting reproductive autonomy: Respecting legally recognised decisions about embryo creation, storage, use, and disposition.

Preventing exploitation: Protecting patients, donors, surrogate mothers, and children from coercion, discrimination, and unlawful financial arrangements.

Regulating research: Establishing lawful boundaries for embryo research, including restrictions on cross-border transfers and prohibited uses.

Ensuring accountability: Providing inspection, complaint mechanisms, penalties, and remedies for regulatory violations.

These objectives require a balance between reproductive freedom, medical innovation, public interest, and the protection of vulnerable persons.

3. Legal framework in India

India's primary statutory framework is the Assisted Reproductive Technology (Regulation) Act, 2021. It came into force on 25 January 2022. The Act regulates ART clinics and banks, embryo storage and handling, consent, research, and restrictions on commercial dealings in reproductive material.

India Code+1

A. Important statutory provisions

These provisions establish a statutory framework for reproductive medicine rather than permitting an unrestricted embryo marketplace.

India Code+1

B. Section 29: Restriction on commercial dealings

Section 29 is central to commercial embryo governance in India.

It prohibits the sale, transfer, or use of human gametes, zygotes, and embryos—or parts thereof and information related to them—directly or indirectly to parties within or outside India, subject to the statutory exception for transfer of one's own gametes and embryos for personal use with permission of the National Board.

IndiaCode+1

The practical implications include:

A business cannot assume it may sell human embryos as ordinary commercial inventory.

Cross-border transfers cannot be treated as automatically lawful merely because a foreign recipient is willing to pay.

A clinic's fees for legitimate medical services must be distinguished from a prohibited transaction involving the embryo itself.

Consent, clinical registration, storage requirements, and research restrictions remain independently relevant.

Important distinction: Charging for lawful IVF treatment or laboratory services is not necessarily the same as selling an embryo. The legality depends on the nature of the transaction and the applicable statutory requirements.

C. Section 28: Storage and handling

Section 28 addresses the security, identification, recording, and storage of human embryos and gametes. The Act provides for a storage period of no more than ten years, after which the material is to be allowed to perish or donated to a registered research organisation with the requisite consent and in the prescribed manner.

Indian Kanoon+1

This provision raises important governance questions:

Who is authorised to make decisions about stored embryos?

What happens when intended parents separate or disagree?

How should clinics manage storage fees, abandoned material, or administrative errors?

What safeguards prevent unauthorised disposal, transfer, or use?

The ten-year rule should be read alongside the applicable rules, consent documents, and any relevant legal orders; it should not be treated as permission for a clinic to dispose of embryos arbitrarily.

D. Sections 22–24: Consent and accountability

Written informed consent, accurate records, and the duties of clinics and banks are essential to lawful embryo governance.

A robust consent process should clearly explain:

The purpose of embryo creation and intended treatment.

Storage arrangements and applicable fees.

Permitted future uses, including any proposed research.

Available choices concerning continued storage and lawful disposition.

The consequences of separation, death, withdrawal of consent, or disagreement.

The limits of the clinic's authority over the embryo.

Consent does not override a statutory prohibition. Equally, the existence of a signed form does not automatically resolve every dispute about the embryo's future use.

E. Relationship with the Surrogacy (Regulation) Act, 2021

The Surrogacy (Regulation) Act, 2021 complements the ART framework. It prohibits commercial surrogacy and regulates surrogacy procedures, eligibility, and the protection of the surrogate mother. Its definition of commercial surrogacy expressly includes buying or selling human embryos and gametes in the context specified by the Act.

Indian Kanoon+1

Consequently, an arrangement involving both embryo transfer and surrogacy may engage two separate statutory regimes. Compliance with one does not automatically establish compliance with the other.

4. Leading case laws relevant to commercial embryo governance

The cases below address embryo consent, reproductive autonomy, privacy, and surrogacy. Not all concern commercial embryo sales directly; they are relevant because they establish principles that courts may apply when reviewing embryo-related regulation and disputes.

Case 1: Evans v. United Kingdom (2007), Application No. 6339/05

European Court of Human Rights, Grand Chamber, judgment of 10 April 2007

Facts: Natalie Evans underwent IVF treatment after being diagnosed with a condition that would prevent her from producing eggs in the future. Embryos were created using her eggs and her former partner's sperm. After their relationship ended, her former partner withdrew his consent to their continued use. Under the applicable UK legislation, the embryos could not be used without both parties' continuing consent.

Legal issue: Whether requiring the former partner's continuing consent, despite the serious consequences for Evans's ability to have a genetically related child, violated her rights under Article 8 of the European Convention on Human Rights.

Decision: The Grand Chamber held that the UK had not violated Article 8. It accepted the importance of the state's policy of requiring continuing consent from both genetic contributors and recognised the state's broad discretion in this ethically sensitive field.

HUDOC+1

Legal principles:

Consent is a central safeguard in embryo governance.

The interests of both genetic contributors can conflict, even when an embryo has already been created.

Reproductive autonomy does not necessarily confer an absolute right to use a jointly created embryo.

Clear legal rules can be justified to provide certainty in reproductive medicine.

Relevance to India: The case is persuasive comparative authority, not binding Indian precedent. It demonstrates why Indian clinics should establish clear consent arrangements before embryo creation and storage. The precise consequences of withdrawal of consent in India must be determined under Indian legislation and applicable judicial decisions.

Case 2: Baby Manji Yamada v. Union of India (2008), (2008) 13 SCC 518

Supreme Court of India

Facts: The case arose from an international surrogacy arrangement involving a Japanese couple. Following the breakdown of their marriage, questions arose concerning the child born through surrogacy, including guardianship, travel documentation, and legal recognition.

Legal issue: How should Indian authorities address the legal status and practical protection of a child born through an international surrogacy arrangement when the intended parents' circumstances change?

Decision: The Supreme Court dealt with the dispute in the context of the child's welfare and the legal and administrative issues surrounding international surrogacy. It did not establish a general right to buy or sell human embryos.

Indian Kanoon+1

Legal principles and relevance:

Reproductive arrangements can create difficult questions of parentage, nationality, custody, and responsibility.

The interests of the resulting child must not be ignored in disputes among adults or commercial intermediaries.

International arrangements require careful attention to the laws of each relevant jurisdiction.

A commercial contract cannot by itself resolve every issue concerning a child's legal status.

Governance lesson: Embryo-related agreements should include lawful and clearly defined arrangements for parentage and the protection of the resulting child, without treating the child as a commercial product.

Note: The case concerned surrogacy, not a direct challenge to the statutory prohibition on embryo sales.

Case 3: Suchita Srivastava v. Chandigarh Administration (2009), (2009) 9 SCC 1

Supreme Court of India

Facts: The case concerned the reproductive rights of a woman with an intellectual disability and the question of whether the state could compel termination of her pregnancy.

Legal issue: Whether reproductive choice forms part of personal liberty and whether the state can override an individual's reproductive decisions without sufficient legal justification.

Decision: The Supreme Court recognised reproductive choice as an aspect of personal liberty under Article 21 of the Constitution. It emphasised that reproductive autonomy includes the right to carry a pregnancy to term, give birth, and raise children, subject to the applicable legal framework.

Legal principles:

Reproductive autonomy is an important constitutional interest.

Medical decisions require respect for the individual's legally protected rights.

State intervention must have a proper legal basis.

The interests and dignity of the individual must remain central to reproductive regulation.

Relevance to commercial embryo governance: The decision supports a rights-based approach to ART regulation. It does not establish ownership rights over embryos or invalidate statutory restrictions on their sale. Rather, it provides a constitutional perspective for evaluating consent procedures, reproductive decisions, and regulatory safeguards.

Case 4: Justice K.S. Puttaswamy (Retd.) v. Union of India (2017), (2017) 10 SCC 1

Supreme Court of India, nine-judge bench

Facts: The case arose from constitutional challenges concerning privacy and the Aadhaar identification framework.

Legal issue: Whether the right to privacy is protected as a fundamental right under the Indian Constitution.

Decision: The Supreme Court unanimously recognised privacy as a fundamental right, grounded in constitutional guarantees including personal liberty and dignity.

Legal principles:

Privacy is integral to personal autonomy and dignity.

Informational privacy is an important component of the constitutional right to privacy.

State interference with protected rights must satisfy applicable constitutional standards.

The collection and use of personal information require appropriate safeguards.

Relevance to commercial embryo governance: IVF clinics and embryo banks may process sensitive information about genetic contributors, fertility treatment, genetic testing, and family relationships. The privacy principles in Puttaswamy support careful controls on access to and disclosure of such information.

However, the judgment is not a direct ruling on embryo ownership, embryo trading, or the precise data-protection obligations of ART clinics. Those questions must be decided under the relevant statutory and constitutional framework.

Case 5: S.H. and Others v. Austria (2011), Application No. 57813/00

European Court of Human Rights, Grand Chamber, judgment of 3 November 2011

Facts: Applicants challenged Austrian restrictions on certain forms of assisted reproduction, including the use of donated reproductive material in IVF treatment.

Legal issue: Whether restrictions on particular ART techniques unjustifiably interfered with the applicants' rights to respect for private and family life under Article 8 of the European Convention on Human Rights.

Decision: The Grand Chamber found no violation of Article 8 in the circumstances, while recognising that reproductive choices fall within the scope of private and family life and that the regulation of assisted reproduction raises complex ethical questions.

Legal principles:

Reproductive treatment can engage the right to respect for private and family life.

States have a role in establishing safeguards for assisted reproduction.

Restrictions must be assessed in light of their justification and the state's discretion in this sensitive field.

Scientific progress can require continuing review of reproductive legislation.

Relevance: This judgment illustrates the tension between access to reproductive technologies and public regulation. It is comparative authority and does not determine the legality of embryo commercialisation in India.

5. Core legal doctrines governing commercial embryos

The following are analytical doctrines that help organise the legal issues. They should not be mistaken for separately enacted Indian doctrines bearing these exact names.

1. Human dignity and non-commodification

Human embryos should not be treated as ordinary merchandise. Indian legislation expressly restricts commercial dealings in embryos, although lawful reproductive services may involve payment for medical care and laboratory work.

2. Informed-consent doctrine

Embryo creation, storage, treatment, and proposed research should follow the applicable consent requirements. A clinic must not assume that payment or possession of stored material substitutes for valid consent.

3. Regulatory accountability

Clinics and banks must comply with registration, recordkeeping, storage, consent, and other statutory obligations. Violations may trigger regulatory action and statutory penalties.

4. Reproductive autonomy

The law must consider the reproductive interests of patients and genetic contributors while recognising that those interests operate within statutory limits and may conflict with one another.

5. Cross-border accountability

International embryo transfers and reproductive arrangements may raise questions of jurisdiction, consent, documentation, and conflicting national laws. Indian statutory restrictions must be considered before any transfer abroad.

6. Legal liability for commercial embryo violations in India

Section 33 of the ART Act prohibits specified conduct, including selling human embryos or gametes, trading in them, and selling embryos or gametes for research. It also prohibits specified forms of exploitation and other conduct identified in the provision.

IndiaCode+1

The statutory penalties under Section 33(2) include:

The precise penalty depends on the statutory offence and the facts established. Section 37 also addresses offences by clinics or banks, so organisational liability must be considered separately where applicable.

Potentially relevant legal consequences include:

Suspension or cancellation of registration.

Criminal proceedings under the applicable provisions.

Liability arising from negligence, breach of duty, or other independently established wrongs.

Judicial proceedings concerning consent, privacy, parentage, or the lawful disposition of embryos.

Not every disagreement over stored embryos constitutes a criminal offence. The legal character of the conduct, applicable statutory elements, and available evidence must be assessed separately.

7. Application to hypothetical situations

These examples illustrate the legal analysis rather than determine the outcome of any particular dispute.

8. Challenges in commercial embryo governance

A. Ownership and control

A central unresolved issue in many jurisdictions is whether stored embryos should be understood through concepts of ownership, consent-based control, reproductive interests, or a distinct legal status.

Indian law restricts commercial dealings but that prohibition alone does not resolve every question about the control, use, or disposition of embryos in disputed circumstances.

B. Scientific developments

Advances in embryo culture, genetic testing, cryopreservation, and reproductive biotechnology can create new legal questions faster than legislation develops.

Regulation must distinguish lawful medical innovation from prohibited activities while protecting patients and maintaining clinical standards.

C. International reproductive markets

Differences among national legal systems can encourage parties to seek treatment abroad. Cross-border arrangements may create uncertainty concerning parentage, consent, records, and the lawful movement of reproductive material.

D. Unequal bargaining power

Patients facing infertility may be vulnerable to misleading claims, high-pressure sales practices, and unclear storage agreements. Donors and surrogate mothers may also face economic or social pressures.

Effective governance therefore requires accessible information, transparent fees, meaningful consent, and credible complaint mechanisms.

9. Recommendations for a stronger governance framework

A well-designed framework for commercial embryo governance should include:

Transparent consent procedures: Standardised forms covering creation, storage, authorised use, withdrawal, and disposition.

Reliable embryo records: Traceable identification, secure access controls, and auditable records of handling and transfer.

Independent inspections: Regular verification of clinic registration, laboratory standards, and compliance.

Clear financial disclosures: Separate billing for lawful medical services and explicit prohibitions on unlawful embryo sales.

Effective grievance procedures: Accessible mechanisms for patients to raise disputes about consent, storage, and alleged misconduct.

Research oversight: Appropriate review of proposed embryo research and strict adherence to statutory restrictions.

Cross-border safeguards: Verification of the legality and authorisation of any proposed international transfer.

Protection of children: Legal and administrative arrangements that prioritise the rights and welfare of children born through ART.

10. Conclusion

Commercial Embryo Governance is best understood as a framework for regulating the intersection of reproductive medicine, commercial activity, constitutional rights, scientific research, and human dignity.

In India, the ART Act, 2021 provides the principal statutory foundation. Sections 22–30 address consent, records, clinical duties, storage, restrictions on commercial dealings, and research, while Sections 31–37 address the rights of children and statutory offences and penalties. The Surrogacy (Regulation) Act, 2021 adds a further layer where surrogacy is involved.

The cases discussed provide complementary principles: Evans concerns continuing consent, Baby Manji Yamada highlights child welfare and international surrogacy issues, Suchita Srivastava addresses reproductive autonomy, Puttaswamy protects privacy, and S.H. v. Austria examines restrictions on assisted reproduction.

Taken together, these authorities support a model in which legitimate reproductive treatment is regulated, commercial exploitation is restricted, consent and privacy are respected, and the interests of resulting children are protected. They do not establish that embryos are ordinary property or create an unrestricted right to commercialise them.

For a more advanced legal study, the next useful step would be a separate case-law analysis focused specifically on Indian Supreme Court and High Court decisions concerning embryo ownership, frozen-embryo disputes, and the constitutionality of restrictions under the ART and Surrogacy Acts.